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Abstract
Background: Colorectal cancer is the third most incident cancer and cause of cancer-related death in the United States.
MicroRNAs, a class of small non-coding RNAs, have been implicated in the pathogenesis and prognosis of colorectal cancer,
although few studies have examined the relationship between germline mutation in the microRNAs with risk and prognosis.
We therefore investigated the association between a SNP in hsa-mir-608, which lies within the 10q24 locus, and colorectal
cancer.
Methods and Results: A cohort consisting of 245 cases and 446 controls was genotyped for rs4919510. The frequency of
the GG genotype was significantly higher in African Americans (15%) compared to Caucasians (3%) controls. There was no
significant association between rs4919510 and colorectal cancer risk (African American: ORGG vs. CC 0.89 [95% CI, 0.41–1.80])
(Caucasian: ORGG vs. CC 1.76, ([95% CI, 0.48–6.39]). However, we did observe an association with survival. The GG genotype
was associated with an increased risk of death in Caucasians (HRGG vs. CC 3.54 ([95% CI, 1.38–9.12]) and with a reduced risk of
death in African Americans (HRGG vs. CC 0.36 ([95% CI 0.12–1.07).
Conclusions: These results suggest that rs4910510 may be associated with colorectal cancer survival in a manner that is
dependent on race.
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Introduction
Colorectal carcinoma is the third most incident cancer and
cause of cancer-related mortality in the United States. Estimates
for 2011 predict 141,210 new cases of colorectal cancer and
49,380 deaths [1]. In the past ten years, there have been significant
advances in our understanding of the natural history and
molecular mechanisms underlying colorectal cancer development.
In addition, substantive guidelines for screening have been
developed by the US Preventative Services Task Force. Thera-
peutic improvements have also been achieved, particularly after
the 2004 approval of bevacizumab (AvastinH) for advanced
disease. Despite these advances, the five-year survival for co-
lorectal cancer has increased only ,5 percentage points in recent
years [1].
Although this survival trend holds true for both African
Americans and Caucasians, a readily apparent health disparity
exists for African Americans. By age 65, African Americans have
an approximate 25% greater probability of developing colorectal
carcinoma compared to Caucasians [1,2]. Additionally, colorectal
cancer incidence in African Americans in 2007 was estimated to
be essentially the same as in 1975, whereas Caucasians have
experienced a 17-percentage point drop in incidence. Twenty four
percent of colorectal cancers are detected at late stage in African
Americans, compared to 19% in Caucasians. This may in part
explain the significantly worse overall survival rate in African
Americans, who have a 15% increased risk of dying from
colorectal cancer when compared to Caucasians [1,2].
MicroRNAs (miRNAs) are a class of small, non-coding RNAs
consisting of approximately 22–25 nucleotides in their processed,
mature form. To date, over 1000 miRNAs have been discovered
in humans, with some estimates predicting a final count of
several thousand [3,4], Physiologically, miRNAs act as a rheostat,
fine tuning translational output through targeted mRNA binding
and repression. The target repertoire of a miRNA is defined
primarily by its seed sequence, nucleotides 2–6 at the 39 end of its
mature form. A variety of pathologic associations have been
attributed to altered miRNA networks particularly in cancer,
with miRNAs able to function as both oncogenes and tumor
suppressors [5,6,7].
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genetic variation in miRNAs to colorectal cancer risk, diagnosis,
prognosis, and drug response [8,9,10,11]. Single nucleotide
polymorphisms (SNPs) in miRNAs can affect their biogenesis,
processing, and/or target site binding in a variety of ways, as
highlighted in our recent review [12]. For example, since
microRNAs are processed in a step-wise fashion from pri to pre
to a mature strand, a process guided by stereotypical secondary
structure, one can conceptualize how a single base pair change
could affect processing or recognition by guide components [12].
Alternatively, a SNP in the mature sequence can alter target site
interactions by either strengthening or weakening hybridization
kinetics, or if in the seed sequence, it can significantly transform
the target library of the miRNA itself. Interestingly, the prevalence
of these SNPs in miRNAs is significantly lower than predicted in
the remainder of the genome, speaking to the evolutionary
conservation and importance of these small biomolecules [13,14].
However, a few reports have recently highlighted an association
between these low frequency germline variations and cancer risk
and/or prognosis [12].
Loss of heterozygosity in the 10q24 locus has been reported in
a number of human cancers, including but not limited to
colorectal, prostate, pancreatic, and brain [15,16,17,18]. Despite
numerous investigations into a possible tumor suppressor gene in
this hotspot, strong evidence is lacking [19]. Interestingly, hsa-mir-
608, a microRNA of which virtually nothing is known functionally,
lies within an intron of SEMA4G in this region. Furthermore, hsa-
mir-608 harbors a SNP, rs4919510, in bp 22 of its mature 25 bp
sequence. This C-G polymorphism is common in several
populations. Here we report that the rs4919510 germline poly-
morphism within hsa-mir-608 is associated with colorectal cancer
survival, in a race-specific manner.
Materials and Methods
Ethics statement
All participants gave written informed consent. The protocol
was in compliance with the Declaration of Helsinki and approved
by the Institutional Review Boards of the National Cancer
Institute. The ethics exemption number is 11289.
Study Population: The NCI-University of Maryland
Colorectal Cancer Case-Control Study
The study population consisted of 691 subjects. Incident
colorectal cancer cases (n=245) and controls (n=446) were
recruited from 1992–2003 and 1998–2003, respectively from the
greater Baltimore, Maryland area. The controls were accrued
from both a hospital setting (n=236) and a community setting
(n=210). The inclusion and exclusion criteria have been pre-
viously described [20]. In brief, subjects were self-reported
Caucasian or African-Americans born in the United States, and
were excluded if they self-reported a history of cancer other than
colorectal, HIV, HBV, HCV, or IV drug use, were institution-
alized, or had a mental impairment. Information to determine
disease stage, treatment, and survival was obtained from medical
records and pathology reports, Social Security Death Index, and
National Death Index. Disease staging was completed according to
the tumor-node-metastasis system of the American Joint Commit-
tee on Cancer. The survival period was determined from date of
hospital admission for surgery to date of last completed search for
death entries in the Social Security Death Index (2010). Informed
consent was obtained from all participants, and epidemiological
questionnaires including, personal history, family medical history,
past medical history, tobacco history, dietary information, and
information on work environment, were administered to all
subjects. The study was approved by the institutional review
boards of the participating institutions.
Genotyping. Genomic DNA was isolated from buffy coat or
colorectal tissue using the Qiagen FlexiGene DNA Kit or the
DNAeasy tissue kit, respectively (Qiagen, Valencia, CA). Cases
Table 1. Demographic characteristics of the NCI-University of Maryland colorectal cancer case control study participants.
Characteristics Cases Population Controls Hospital Controls Total Controls
n 245 236 210 446
Age 6 SD 64.7611.7 66.869.7 63.1612.1 65.0611.0
Gender (%)
Male 185 (75)
1 115 (48) 97 (46) 212 (48)
Female 60 (25) 121 (51) 113 (54) 234 (52)
Race (%)
African American 97 (40) 121 (51) 69 (33) 190 (43)
Caucasian 148 (60) 115 (49) 141 (67) 256 (57)
Stage (%)
Unknown 4 (31)
I 38 (16)
II 69 (29)
III 79 (33)
IV 51 (21)
Survival Time (months)
Median, range 50.5 (43.2–56.4)
1Statistically significant; p-value,0.05 vs. each control group.
doi:10.1371/journal.pone.0036306.t001
rs4919510 in Colorectal Cancer
PLoS ONE | www.plosone.org 2 May 2012 | Volume 7 | Issue 5 | e36306and controls were genotyped using the Taqman assay (Life
Technologies, Carlsbad, CA) for rs4919510 in mir-608 at Ohio
State University Genotyping Core. The case, control, negative
controls, and duplicate samples were randomly distributed for
order of processing, with 10% duplicates to test both inter- and
intra-plate concordance. All parties involved in genotyping were
blinded to the case, control, and duplicate status of the samples.
Samples that failed to genotype were recorded as undetermined.
Both inter- and intra-plate duplicates were 100% concordant. The
completion rate was 98%.
KRAS mutation analysis. Samples with tumor tissue were
sent for KRAS mutation analysis at Bioserve (BioServe Bio-
technologies, Ltd. Beltsville, MD). DNA was extracted using
Trizol
TM according to the manufacturer’s instructions. The
following mutations were assessed: codon 12 (nucleotide 1;
0.8%), codon 12 (nucleotide 2; 20%), codon 13 (nucleotide 1;
2.3%) and codon 61 (nucleotide 3; 0.8%). Data in this study is
represented as normal or mutant for any one of the mutations
outlined above (26% overall).
Statistical Analysis. Statistical analyses were performed
using STATA 11.0 (College Station, TX). A p-value of less than
0.05 was used as the criterion for statistical significance, and all
statistical tests were two-sided. Departures from Hardy-Weinberg
equilibrium were determined using a x
2 test. Odds ratios (OR) and
their corresponding 95% confidence intervals (CI) were estimated
using a univariable unconditional logistic regression model and an
adjusted model that included the covariates age (continuous) and
gender (categorical). Hazard ratios (HR) and 95% CI were
estimated using a univariable Cox proportional hazards regression
model and an adjusted model for the covariates age (continuous),
gender (categorical) and stage of disease (categorical). Survival
time was calculated from date of surgery to date of either last
known follow up (last NDI update 12/31/2008) or date of death
due to colorectal cancer. Of the 245 patients, there were 117
events, 52 of which were in African Americans, 45 of which were
Table 2. Association of rs4919510, a SNP in mir-608, with colorectal cancer risk.
Stratification Genotype Cases N (%)
Controls
N (%)
Univariable OR
(95% CI) p-value
Multivariable
2 OR
(95% CI) p-value
All CC 124 (52) 231 (53) Reference 0.743 Reference 0.183
CG 96 (40) 166 (38) 1.06 (0.75–1.48) 0.393 1.28 (0.89–1.84) 0.910
GG 19 (8) 36 (8) 0.78 (0.43–1.39) 0.831 0.96 (0.51–1.82) 0.521
p-trend 1.03 (0.80–1.31) 1.09 (0.84–1.43)
African Americans CC 34 (36) 62 (34) Reference 0.550 Reference 0.662
CG 48 (51) 95 (51) 1.17 (0.69–1.98) 0.689 1.13 (0.66–1.93) 0.619
GG 12 (13) 28 (15) 0.86 (0.41–1.80) 0.553 0.83 (0.39–1.78) 0.795
p-trend 0.89 (0.62–1.30) 0.95 (0.66–1.37)
Caucasians CC 90 (62) 169 (68) Reference 0.221 Reference 0.125
CG 48 (33) 71 (29) 1.36 (0.83–2.23) 0.393 1.49 (0.89–2.49) 0.622
GG 7 (5) 8 (32) 1.76 (0.48–6.39) 0.190 1.40 (0.37–5.27) 0.145
p-trend 1.27 (0.89–1.83) 1.38 (0.89–2.13)
2Adjusted for age, gender, and race (where applicable).
doi:10.1371/journal.pone.0036306.t002
Table 3. Association of rs4919510 with colorectal cancer survival.
Stratification Genotype
Alive
N (%)
Deceased
N (%)
Univariable HR
(95% CI) p-value
Multivariable
3 HR
(95% CI) p-value
All CC 66 (53) 58 (50) Reference 0.764 Reference 0.794
CG 48 (39) 48 (42) 1.06 (0.72–1.56) 0.883 1.06 (0.70–1.60) 0.581
GG 10 (8) 9 (8) 1.05 (0.52–2.13) 0.730 1.23 (0.59–2.60) 0.608
p-trend 1.04 (0.78–1.39) 1.09 (0.79–1.49)
African Americans CC 13 (30) 21 (42) Reference 0.243 Reference 0.271
CG 23 (52) 25 (50) 0.70 (0.39–1.27) 0.082 0.72 (0.40–1.30) 0.066
GG 9 (18) 4 (8) 0.38 (0.13–1.13) 0.059 0.36 (0.12–1.07) 0.180
p-trend 0.65 (0.42–1.02) 0.72 (0.45–1.16)
Caucasians CC 53 (66) 37 (57) Reference 0.406 Reference 0.220
CG 25 (31) 23 (35) 1.25 (0.74–2.10) 0.009 1.41 (0.81–2.44) 0.027
GG 2 (32) 5 (8) 3.54 (1.38–9.12) 0.046 2.95 (1.13–7.71) 0.030
p-trend 1.52 (1.01–2.31) 1.57 (1.05–2.37)
3Adjusted for age, gender, race, and stage.
doi:10.1371/journal.pone.0036306.t003
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visual inspection of log-log plots and using a non-zero slope test of
the Schoenfeld residuals [21] (p=0.91 for African Americans,
p=0.79 for Caucasians). The method of Kaplan and Meier was
used for plotting genotypes and survival, where death due to
colorectal cancer was again considered as the endpoint. These
graphs were generated using SigmaPlot 12.0 (Systat Software, San
Jose, CA). Significance was tested using the Log-Rank method.
Tests for linear trend were also conducted by including the
genotype variable in the model as a continuous ordinal variable
(Ptrend). Differences in rs4919510 genotypes in normal versus
mutant KRAS tumors were assessed using Fisher’s exact test.
Results
Study population and miR-608 genotype analysis
We investigated the relationship between rs4919510, a SNP in
the mature sequence of hsa-mir-608, with regards to risk and
disease outcome in 245 colorectal cancer cases and 446 controls.
Relevant population characteristics are described in Table 1.
Overall, the cases did not differ from the controls in terms of age
or race; however, the case cohort contained significantly more
males than each respective control group (population, hospital, or
total) (Table 1). The minor allele frequency [22] of rs4919510 was
significantly higher in African Americans, compared to Cauca-
sians; 40.5% and 17.5%, respectively (Table 2). In addition, the
frequency of the GG genotype was significantly higher in African
Americans (15%) compared to Caucasians (3%) controls, in
agreement with observations for this SNP in HapMap [23]. Since
the frequencies of rs4919510 genotypes did not differ between
hospital and population control groups, all analyses are presented
using the overall control group (Tables 2 and 3). Rs4919510 did
not deviate from Hardy-Weinberg equilibrium proportions in
either the population or hospital controls.
No association between rs4919510 and colorectal cancer
risk
The GG or CG genotypes of rs4919510 were not associated
with colorectal cancer risk (Table 2). In the total population, the
frequency of the GG genotype was 8% in cases and 8% in
controls. In African Americans, the GG genotype was represented
in 15% of controls, and 13% of cases, corresponding to an
adjusted OR of 0.89 (95% CI, 0.41–1.80). In Caucasians, the GG
genotype was present in 3% of controls and 5% of cases, with an
OR of 1.76, (95% CI, 0.48–6.39). There is no association between
the SNP and KRAS mutation status in the whole cohort. In
African Americans, it was notable that the GG genotype was not
observed in mutant KRAS tumors, but the difference did not
reach statistical significance (Figure S1).
Association between rs4919510 and colorectal cancer
survival
We found a significant association between rs4919510 and
colorectal cancer survival. In Caucasians, the homozygous variant
genotype, GG, was associated with a significant increase in risk of
death from colorectal cancer represented by a univariable hazard
ratio (HR) of 3.54 (95% CI, 1.38–9.12), which remained
significant after adjustment for age, gender, histology and stage
in our multivariable model; HRGG vs. CC 2.95 (95% CI, 1.13–7.71)
(Table 3) (Figure 1A). The CG genotype also showed a trend
towards poor outcome, although the comparison to the CC
referent genotype was not statistically significant (Table 3).
In African Americans, we observed a protective association
between the GG genotype and survival, although the model
approached significance in both the adjusted (HR GG vs. CC 0.38
[95% CI, 0.13–1.13; p=0.082]) and non-adjusted (HR GG vs. CC
0.36 [95% CI, 0.12–1.07; p=0.066]) models (Table 3) (Figure 1B).
Kaplan-Meier survival curves graphically depict the divergent
effects of this SNP in these populations (Figure 1). No significant
survival associations were found when rs4919510 was analyzed
without stratification, or when the cohort was stratified respective
of cancer stage (Table 3 and Data not shown).
Figure 1. Rs4919510 and colorectal cancer survival stratified
by race. Kaplan Meier survival curves depicting the relationship
between rs4919510 and colorectal cancer survival in A) Caucasians
(n=145) and B) African Americans (n=94). Censored individuals are
indicated with a closed circle.
doi:10.1371/journal.pone.0036306.g001
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Our results show an association between a germline variant in
hsa-mir-608 with prognosis, but not risk, of colorectal cancer. In
Caucasians, it was associated with an increased risk of death due to
colorectal cancer. However, a trend towards the opposite effect
was observed in African Americans. Previous studies have also
demonstrated how race can modulate the effect of a SNP in
colorectal cancer [24]. Of note however, while the association was
statistically significant in Caucasians (n=145), the association only
approached significance in African Americans. This could suggest
that the relationship is not epidemiologically relevant, but given
the smaller number of individuals in the African American group
(n=94), it is perhaps more reflective of our reduced power. In
both populations, the SNP was associated with survival in
a recessive model.
While this manuscript was in preparation, Xing et al. published
a study on colorectal cancer prognosis in association with
rs4919510 within a Chinese population with 408 patients [25].
They reported that the variant allele (C) was associated with
a reduced risk of recurrence-free and overall survival (HR=0.61,
95% CI=0.41–0.92), therefore, the G allele was associated with
adverse outcome. This is in general agreement with our findings in
Caucasians. Xing et al. did not include a control arm to examine
risk associations, though as described above, our results do not
support a role for this SNP in colorectal cancer. These studies
strengthen the hypothesis that there is an association between
rs4919510 and colorectal cancer prognosis that might be race-
specific.
While we cannot currently explain the exact functional
mechanism through which this SNP may affect colorectal cancer
prognosis, there are several plausible hypotheses. As mentioned
before, rs4919510 lies within the mature sequence of miR-608,
and is located at the joint of the stem with the canonical hairpin
loop. Since this rigid secondary structure is a requisite for
recognition, and thus processing, of precursor miRNA by the
RNAse Drosha, it is feasible that disruption of structure at this
critical point might affect recognition or subsequent processing.
Each miRNA has hundreds of targets, thus a singular change in
a cell’s miRNA kinetic profile could have an exponentially large
effect on protein output, perhaps having an effect so large it could
skew, even slightly, overall prognosis of a disease.
A change in a miRNA’s mature sequence could also theoret-
ically alter its target repertoire once processed [26,27]. Although
rs4919510 does not lie within the seed sequence of miR-608,
hybridization kinetics outside of this region have been shown to be
important in target recognition [28]. The exact importance,
relative weight, and subsequent shifting of preference due to
miRNA sequence variations has yet to be fully elucidated, though
examples exist [12]. An extension of this principle could be applied
to the SNP in hsa-mir-608 in relation to colorectal cancer, whose
putative targets include BCL-xL, SEPT9, and CDK6 (www.
targetscan.org). Indeed, an alteration in transcript targeting by
miR-608 to any of those genes could have consequences directly
related to cancer cell survival.
Interestingly, Xing et al. also reported that the association
between the GG genotype and poor outcome was only observed in
those patients who had been treated with chemotherapy, the
majority of which had been on a FOLFOX regimen. Interestingly,
miR-608 is predicted to target at least 2 of the key enzymes
involved in activation of 5-FU, thymidine kinase and folylpolyglu-
tamate synthase (www.targetscan.org). In addition, there have
been several studies examining variant chemotherapeutic response
rates in colorectal carcinoma by race. In one study, although time
to disease progression was not affected by race, a significantly
higher percentage of Caucasians responded to a FOLFOX or
IROX regime [29]. Therefore, rs4919510 could theoretically play
a role in differential response rates to chemotherapeutics across
populations.
In addition to a putative functional association with miR-608,
linkage disequilibrium with SNPs in neighboring genes cannot be
ruled out. Of note, there is significantly less linkage predicted for
rs4919510 from current 1000 genomes data in the African
American population, where only 7 SNPs in 2 unique genes are
predicted to be in linkage disequilibrium with rs4919510, as
opposed to 39 SNPs in 5 unique genes in Caucasians (www.
broadinstitute.org/mpg/snap/ldsearch.php#,r
2.0.8 and distan-
ce,500 kb). Of particular interest among the list of differentially
linked gene alleles in Caucasians is leucine zipper tumor
suppressor 2 (LZTS2), which contains several SNPs in the first
intron and 59 UTR predicted to be strongly associated with
rs4919510. Recent findings from two separate studies have shown
that knockdown of LZTS2 expression sensitizes cells to paclitaxel
therapy in addition to antagonizing proliferation of several cancer
cell lines by down-regulation of myc and cyclin D1 through
engagement of the NF-kB pathway [30,31]. If the G allele of
rs4919510 is truly in linkage with a SNP in LZTS2, the expression
of this gene may be altered, contributing to the poor prognosis of
this variant genotype in our Caucasian cohort. However, this
hypothesis remains to be investigated.
In summary, our study validates the hypothesis that a SNP in
the mature sequence of hsa-mir-608 can significantly affect the
prognosis of colorectal cancer patients. Interestingly, this effect of
this SNP seems to vary by race, as demonstrated by our findings
and others [25]. While the association between this SNP and
colorectal cancer survival is notable as demonstrated in three
cohorts, further studies should be conducted to confirm the race-
specific nature of the SNP’s effect. In addition, exploration of the
functional role of this SNP, the mechanism of its interaction with
5-FU, as well as its potential involvement in other cancers is
warranted.
Supporting Information
Figure S1 rs4919510 and KRAS mutation status. Percentage of
KRAS mutations in rs4919510 CC, CG and GG samples in the
whole population A), Caucasians B), and African Americans C).
Exact percentages shown in D). WT denotes wild-type, mut
denotes mutant.
(PDF)
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